Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AN INTERVENTIONAL, RANDOMIZED, ACTIVE-CONTROLLED, PHASE 1/2/3 STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF BNT162b RNA-BASED VACCINE CANDIDATES IN COVID-19 VACCINE-EXPERIENCED HEALTHY INDIVIDUALS

NCT05472038 is registered in ClinicalTrials.gov with BioNTech SE as lead sponsor.

NCT NCT05472038
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05472038 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AN INTERVENTIONAL, RANDOMIZED, ACTIVE-CONTROLLED, PHASE 1/2/3 STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF BNT162b RNA-BASED VACCINE CANDIDATES IN COVID-19 VACCINE-EXPERIENCED HEALTHY INDIVIDUALS
Lead sponsor
BioNTech SE
Phase
Phase 2/3
Overall status
Completed
Start date
July 26, 2022
Completion date
March 26, 2024
Enrollment
1,453 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, sars-cov-2 infection